本文選題：乳房Paget病 + 乳房外Paget病��； 參考：《吉林大學(xué)》2010年博士論文

【摘要】： 目的:檢測(cè)相關(guān)蛋白表達(dá),探討PD細(xì)胞起源及腫瘤生物治療;分析臨床病理及治療參數(shù)與預(yù)后和復(fù)發(fā)關(guān)系,指導(dǎo)治療前正確評(píng)估,降低復(fù)發(fā)率。方法:回顧性對(duì)比分析62例PD的臨床病理及治療資料。免疫組化方法檢測(cè)ER,PR,AR,E-cad,GCDFP-15,MUC5AC,HER-2/neu蛋白表達(dá),結(jié)果采用半定量分析。數(shù)據(jù)進(jìn)行統(tǒng)計(jì)學(xué)分析,P0.05認(rèn)為有統(tǒng)計(jì)學(xué)意義。結(jié)果:觸及乳腺腫塊、腋窩淋巴結(jié)腫大、乳腺X線可疑征象及伴有IDC與MPD患者預(yù)后有關(guān);腫瘤的侵潤(rùn)生長(zhǎng)深度及腫瘤邊界清晰與否與EMPD復(fù)發(fā)有關(guān);MPD組腫瘤細(xì)胞主要表現(xiàn)為垂直生長(zhǎng)趨勢(shì),EMPD組腫瘤細(xì)胞主要表現(xiàn)為水平播散生長(zhǎng)趨勢(shì)。所有病例均表達(dá)CK7,MUC1;ER,PR,AR,GCDFP-15,MUC5AC,HER-2/neu,E-cad在MPD組表達(dá)分別為4.8%,0%,35.7%,50%,11.9%,88.1%,64.3%;在EMPD組的表達(dá)分別為0%,0%,80%,80%,60%,50%,45%。結(jié)論:MPD及EMPD本質(zhì)為原發(fā)表皮內(nèi)汗腺癌,兩種疾病生物學(xué)行為不同,抗雄性激素及曲妥珠單抗的治療可作為一種輔助治療方法;乳腺腫塊、腋窩淋巴結(jié)腫大、乳腺X線可疑征象及伴有IDC可作為MPD患者預(yù)后不良的危險(xiǎn)因素;腫瘤的侵潤(rùn)生長(zhǎng)深度及腫瘤邊界清晰與否可作為影響EMPD復(fù)發(fā)的危險(xiǎn)因素。
[Abstract]:Objective: to detect the expression of related proteins, to investigate the origin of PD cells and tumor biotherapy, to analyze the relationship between clinicopathological parameters and prognosis and recurrence, to guide the correct evaluation before treatment and to reduce the recurrence rate. Methods: the clinicopathological and therapeutic data of 62 cases of PD were analyzed retrospectively. Immunohistochemical method was used to detect the expression of HER-2 / neu protein in AR-AR-E-cadGCDFP-15 / MUC5ACHER-2 / neu protein. The results were semi-quantitatively analyzed. The data were statistically analyzed and considered statistically significant (P0.05). Results: involvement of breast masses, enlargement of axillary lymph nodes, suspicious signs of mammography and prognosis of patients with IDC were related to the prognosis of patients with MPD. The depth of tumor invasion and the clarity of tumor boundary were related to the recurrence of EMPD. The tumor cells in EMPD group showed vertical growth trend and horizontal spreading growth trend. All cases expressed CK7C5ACHER-2neuE -cad in the MPD group, the expression of HER-2neuE-cad in the MPD group was 4.80.35. 7%, and the expression in the EMPD group was 11.988. 1 and in the EMPD group, the expression was respectively 0 / 0 / 80 / 8080 / 80 / 60 and 50 / 45 / 4545, respectively, in the EMPD group, the expression of HER-2NU E-cad in the MPD group was 4.890 / 55.The expression of HER-2neuE-cad in the EMPD group was 4.80%, respectively. Conclusion the biological behavior of the two diseases is different. The treatment of anti-androgen and tritozumab can be used as an adjuvant treatment for breast mass, axillary lymph node enlargement, breast mass, axillary lymphadenopathy, breast mass, axillary lymphadenopathy, breast mass, axillary lymphadenopathy, breast mass, axillary lymph node enlargement, The suspicious signs of mammography and IDC may be the risk factors for the poor prognosis of MPD patients, and the depth of tumor invasion and the clarity of tumor boundary may be the risk factors for the recurrence of EMPD.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2010
【分類號(hào)】：R739.5

【引證文獻(xiàn)】

相關(guān)期刊論文 前1條

1 高暉;陳敬;王劍歌;徐家淳;趙志恒;張仁倩;;乳房外Paget病發(fā)病機(jī)制探討(綜述)[J];中國(guó)城鄉(xiāng)企業(yè)衛(wèi)生;2014年01期

，

本文編號(hào)：1788126